Victory Capital Management Inc. Acquires 71,980 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Victory Capital Management Inc. boosted its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 21.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 406,430 shares of the biotechnology company's stock after purchasing an additional 71,980 shares during the quarter. Victory Capital Management Inc. owned about 1.33% of AnaptysBio worth $7,556,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ANAB. Charles Schwab Investment Management Inc. increased its holdings in AnaptysBio by 3.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 166,054 shares of the biotechnology company's stock worth $2,199,000 after purchasing an additional 5,733 shares in the last quarter. Swiss National Bank increased its holdings in AnaptysBio by 12.1% in the fourth quarter. Swiss National Bank now owns 29,700 shares of the biotechnology company's stock worth $393,000 after purchasing an additional 3,200 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in AnaptysBio in the fourth quarter worth approximately $40,000. Vanguard Group Inc. increased its holdings in AnaptysBio by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after purchasing an additional 143,584 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in AnaptysBio by 240.6% in the fourth quarter. JPMorgan Chase & Co. now owns 114,939 shares of the biotechnology company's stock worth $1,522,000 after purchasing an additional 81,195 shares in the last quarter.

Insider Transactions at AnaptysBio

In related news, Director Hollings Renton sold 20,925 shares of the company's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the sale, the director owned 4,965 shares in the company, valued at approximately $117,025.05. This represents a 80.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 33.50% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on ANAB. Guggenheim reiterated a "buy" rating and issued a $90.00 target price (up from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th. Wedbush reiterated an "outperform" rating and issued a $40.00 target price on shares of AnaptysBio in a report on Thursday, May 29th. JPMorgan Chase & Co. boosted their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a report on Thursday. Finally, HC Wainwright upgraded AnaptysBio from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $22.00 to $38.00 in a report on Wednesday, June 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, AnaptysBio has a consensus rating of "Moderate Buy" and a consensus target price of $47.13.

AnaptysBio Trading Down 0.2%

Shares of AnaptysBio stock opened at $26.94 on Friday. The stock has a fifty day simple moving average of $23.62 and a 200 day simple moving average of $19.84. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $41.31. The company has a market capitalization of $791.50 million, a P/E ratio of -5.55 and a beta of -0.27.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 282.47% and a negative net margin of 125.70%. The business had revenue of $27.77 million during the quarter, compared to the consensus estimate of $15.27 million. On average, analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.